Research and Markets: New Report Examines Hot Topics and Key Issues for Prostrate Cancer Treatment
Posted on: Thursday, 24 March 2005, 12:00 CST
DUBLIN, Ireland, March 24 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c14527) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment in the USA to their offering.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. This Insight details physician opinion of currently available products and disease management practice and what they require in the future.
AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists. Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
Topics covered include:
- Quantitative treatment data from 80 physicians from the US
- Qualitative feedback on key findings and future trends in the treatment
of prostate cancer and the management of disease and treatment side
effects
- Coverage of the hot topics affecting current treatment patterns, from
the impact of IMRT on brachytherapy to the increasing use of
bisphosphonates
- A strong future focus on key issues, including the increasing use of
third generation cytotoxics in HRPC
This information will enable readers:
- Identify hot topics and key issues for practicing prostate cancer
specialists the questions they really want answered
- Predict future trends in the treatment of prostate cancer and how to
capitalize on forthcoming changes in treatment practice
- Plan product development to fill prostate cancer market niches as
defined by practicing physicians
For more information visit http://www.researchandmarkets.com/reports/c14527
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980
Photo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH
Research and Markets
CONTACT: Laura Wood, Senior Manager, Research and Markets,press@researchandmarkets.com, Fax: +353-1-4100-980
Web site: http://www.researchandmarkets.com/reports/c14527
Source: PRNewswire
Related Articles
- Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
- Experts Urge Congress To Fund Prostate Cancer Research
- Workout Fundraising Event to Support Prostate Cancer Research
- Safeway Customers and Employees Give $13.2 Million Boost to Prostate Cancer Research Programs
- Safeway Kicks Off Month of Events and Fundraising for Prostate Cancer Research and Awareness
- Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent Through 2012
- European Prostate Cancer Therapeutics Market Supported By Enhanced Awareness
- Cougar Biotechnology Presents Positive CB7630 Phase I Data at the AACR Innovations in Prostate Cancer Research Conference
- New Program Encourages Athletes to Aim for the Finish Line for Prostate Cancer Research
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds